Bicuspid Aortic Valve and Thoracic Aortic Aneurysm Toward a Unified Theory⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology. by Silberbach, Michael
B
a
T
M
P
I
s
w
d
h
f
fi
B
t
t
e
i
t
s
B
v
t
o
(
a
s
f
B
h
g
o
b
c
d
t
J
h
o
t
b
i
u
t
a
t
t
t
t
d
m
g
b
d
o
p
b
p
p
e
i
s
p
D
h
l
o
m
m
f
fi
b
i
o
M
fi
(
i
a
a
t
m
o
a
u
m
f
t
*
v
A
H
Journal of the American College of Cardiology Vol. 53, No. 24, 2009
© 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2009.03.028EDITORIAL COMMENT
icuspid Aortic Valve
nd Thoracic Aortic Aneurysm
oward a Unified Theory*
ichael Silberbach, MD
ortland, Oregon
n this issue of the Journal, Biner et al. (1) report that a
ignificant number of first-degree relatives of individuals
ith bicuspid aortic valve (BAV) have more stiff, less
istensible, and pathologically enlarged aortas despite their
aving completely normal aortic valves. That BAV is a
amilial disease is established (2). The present study is the
nal word in the debate over the relative insignificance of
AV as a cause of aortic dissection in the heritable aortopa-
hy known as familial thoracic aortic aneurysm and dissec-
ion (FTAAD). Indeed, this study and the work of Loscalzo
t al. (3), in which BAVs were found among relatives of
ndividuals with tri-leafleted nonstenotic aortic valves and
horacic aortic aneurysms, refute the belief, held closely by
ome (4), that ascending aortic enlargement in the setting of
AV is caused solely by disturbed flow through an abnormal
alve, the so-called post-stenotic dilation. Other corrobora-
ive studies fail to show any correlation between the severity
f aortic valve stenosis/regurgitation and aortic dimension
5–7). Furthermore, these studies suggest that BAV disease
nd FTAAD might best be understood as variable expres-
ions of the same disease.
See page 2288
Although Biner et al. (1) rule out the absolute necessity
or turbulent flow or high-velocity jets, or the presence of
AV itself in the pathogenesis of aortic aneurysm, others
ave clearly shown that aortic stenosis is correlated with the
rowth rate of the aorta (8) and is predictive of clinical
utcome (9). These observations should come as no surprise
ecause an interaction between hemodynamic state and the
omposition of the aortic wall in the pathogenesis of
issecting aortic aneurysm has been recognized for a long
ime. For example, the eminent cardiac pathologist, Dr.
esse Edwards, in a landmark 1978 report (10) showing the
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.t
From the Department of Pediatrics and Doernbecher Children’s Hospital, Oregon
ealth and Science University, Portland, Oregon.igh incidence of nonobstructive BAV among autopsy cases
f aortic dissection, concluded that “dissecting aneurysm of
he aorta may be viewed as a complication of disproportion
etween the strength of the aorta, on one hand, and
ntraluminal pressure, on the other.” The misapprehension,
ntil now, was the pervasive notion that an acquired injury
o the aortic wall caused by disrupted flow through the
ortic valve, the stress induced by high blood pressure, and
he ravages of aging were primarily or solely responsible for
he disease.
We can now be certain that a complete understanding of
he pathogenesis of aortic aneurysm will require an elucida-
ion of both the genetic triggers of aortic disease and their
ownstream molecular targets. A number of researchers,
ost notably Harry C. Dietz, a Hughes Institute investi-
ator at Johns Hopkins University, have already generated a
ody of compelling evidence by studying families with aortic
isease and mutations in genes that encode either regulatory
r structural proteins. The results of these investigations
oint to the need to understand the complex interactions
etween signal transduction pathways and structural com-
onents of the aorta. This fundamental idea was recently
roposed by Dietz (11) as an alternative explanation for the
tiology of aortic aneurysm in Marfan syndrome. Previously
t was believed that the causative gene defect in Marfan
yndrome, mutations in the gene encoding fibrillin-1, acted
renatally to decrease the elastin content of the aorta.
isease progression was thought to result from postnatal
emodynamic stresses that disrupted the internal elastic
aminae of the aortic wall, producing the histological finding
f cystic medial necrosis.
Dietz’s (11) breakthrough was the observation that in a
ouse model of Marfan syndrome, fibrillin-1 is essential to
aintain the integrity of the elastin fiber but is not required
or generation of elastin prenatally. Most researchers in the
eld have abandoned the acquired weakness hypothesis
ased on evidence provided by Dietz and others (12,13) that
ntracellular signals regulating cell proliferation, migration,
r programmed cell death are important. The recognition by
aslen et al. (14), of structural homology between
brillin-1 and a protein called transforming growth factor
TGF)- binding protein suggested that there might be an
nteraction between the cytokine TGF- signaling pathway
nd the abnormal fibrillin-1 protein. This hypothesis led to
series of elegant experiments showing that TGF- neu-
ralizing antibody reverses aortic disease in an engineered
ouse model of Marfan syndrome (15). Subsequent dem-
nstration (reported in the same publication) that the
ngiotensin II receptor blocker, losartan, by inhibiting
pstream TGF- pathways, essentially cured the Marfan
ouse of dissecting aortic aneurysm was a scientific tour de
orce that has been rarely seen in our generation.
Of course the unanswered question is: To what extent can
he Marfan–TGF- story be generalized to other aortopa-
hies? With regard to FTAAD, the responsible genes are
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June 16, 2009:2296–7 Bicuspid Aortic Valve and Thoracic Aortic Aneurysmargely unknown. So far, 5 gene loci have been identified
16–21), and at least 1 of them has been associated with
utations in TGF- receptor signaling (21). Mutations in
he gene ACTA2 encoding smooth muscle cell alpha actin
ccounts for 14% of FTAAD (17) and previously reported
utations in the gene MYH11 (15) (beta myosin heavy
hain) suggest that maintenance of contractile function of
ortic smooth muscle cells is also important. Whether there
ill be a sort of unified field theory for the molecular
athways that predispose to aortic aneurysm that ultimately
rovides clinicians with the tools to intervene at critical
oints along the path leading to aortic dissection remains an
pen question.
The good news is that the National Heart, Lung, and
lood Institute and the National Institute of Arthritis and
usculoskeletal and Skin Diseases have established a reg-
stry that is collecting medical data and biological material
rom patients with genetic conditions that may be related to
horacic aortic aneurysms. This program, called GenTAC
Genetically Triggered Thoracic Aortic Aneurysms and
ardiovascular Conditions) (22), includes 5 regional centers
cross the U.S. GenTAC’s goal is to make widely available
bioinformatic infrastructure specifically related to aortic
isease. The genius of the GenTAC project is to attract the
est and the brightest in the field of aortic disease and to
ffer them the clinical information and the biological
aterials to generate and test new hypotheses. If it works,
he competition that for too long has hindered many
cientific advancements will yield collaborations that effec-
ively move the project forward.
eprint requests and correspondence: Dr. Michael Silberbach,
epartment of Pediatrics, CDRC-P, Oregon Health and Science
niversity, 3181 SW Sam Jackson Park Road, Portland, Oregon
7239. E-mail: silberbm@ohsu.edu.
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